Visiongain’s latest report, mRNA Vaccines Market Report 2026-2036, provides detailed forecasts and strategic analysis across vaccine type, application, and end-user segments, including technology trends, trade and supply chain dynamics, and competitive positioning.

The global mRNA vaccines market is projected to grow from US$9.7 billion in 2026 to US$16.8 billion by 2031 and US$34.7 billion by 2036, at a CAGR of 13.6% during the forecast period. Annual growth rates are forecast at 7.9% in 2026, 14.5% in 2031, and 16.2% in 2036, driven by advances in lipid nanoparticle delivery systems, the clinical maturation of self-amplifying mRNA platforms, and expanding application of mRNA technologies across oncology and autoimmune indications.

Key Market Insights

• The global mRNA vaccines market will reach US$34.7 billion by 2036, growing at a CAGR of 13.6%
• Growth is driven by delivery system innovation, expanding therapeutic applications, and increasing government investment in mRNA manufacturing capacity
• Key regions: North America, Europe, Asia Pacific
• Leading companies: BioNTech SE, Moderna, Pfizer, GSK, Sanofi
• Key trend: Expansion of mRNA platforms beyond infectious disease into personalised cancer vaccines and immune-mediated conditions

Download Sample Request

Market Drivers

Technological Advancements in Delivery Systems

Advances in mRNA vaccine delivery are focused on optimising ionisable lipid structures to enhance cytosolic delivery while controlling inflammatory signalling. Refinements to lipid head groups, hydrophobic tails, and lipid-to-mRNA ratios are improving protonation behaviour, membrane fusion efficiency, and intracellular mRNA release. Structure-activity studies indicate that even minor changes in lipid composition can significantly influence biodistribution and transfection efficiency, highlighting the precision required at the molecular design level.

Innovation is also extending beyond conventional lipid nanoparticles toward organic and polymer-based delivery systems aimed at improving biodegradability and reducing toxicity without compromising encapsulation performance. In November 2025, Acuitas Therapeutics presented next-generation lipid nanoparticle advances at the International mRNA Health Conference in Berlin, demonstrating improved potency, enhanced safety profiles, and expanded extra-hepatic delivery capability with stronger cancer vaccine performance.

Government Investment and Policy Support

Government-led initiatives are increasingly shaping mRNA vaccine development through targeted funding and coordinated preparedness strategies. In September 2025, the Australian Government allocated AU$19 million through the Medical Research Future Fund to support mRNA-based research for cancer prevention and disease treatment. South Korea advanced a national avian influenza vaccine development programme with SK bioscience under a government-led framework. In September 2025, the UK Government announced the opening of Moderna’s Innovation and Technology Centre in Oxfordshire alongside a £50 million Life Sciences R&D Fund, strengthening domestic mRNA manufacturing capability through public-private collaboration.

Technology & Innovation

Self-Amplifying mRNA Platform Maturation

Self-amplifying mRNA (saRNA) platforms are entering a phase of technical maturation driven by advances in replicon engineering, backbone diversification, and controlled modulation of innate immune responses. Modifications to untranslated regions, cap structures, poly(A) configurations, and immune-modulating elements have delivered more than ten-fold improvements in protein expression compared to earlier designs. Comparative studies confirm that saRNA achieves equivalent or greater protein output at significantly lower doses than conventional non-amplifying mRNA, supported by prolonged in vivo expression.

In March 2025, CEPI awarded approximately US$13.38 million to Gennova Biopharmaceuticals to advance a self-amplifying mRNA Nipah vaccine, integrating AI-enabled antigen optimisation with Houston Methodist Research Institute and supporting progression toward Phase I evaluation.

Trade & Supply Chain Dynamics

Global trade dynamics are directly increasing the cost base of mRNA vaccine manufacturing through tariffs on pharmaceutical inputs, bioprocessing equipment, lipid nanoparticle components, and cold-chain infrastructure. The mRNA manufacturing ecosystem relies on internationally sourced raw materials including nucleotides, capping reagents, enzymes, filtration systems, and GMP-grade single-use components, creating exposure to tariff-related cost pressures and supply-chain constraints.

Smaller biotechnology companies and emerging mRNA manufacturers face greater exposure due to their dependence on outsourced manufacturing and imported materials. Larger developers are accelerating localisation of production capacity, diversification of supplier networks, and strengthening of domestic fill-finish operations to reduce cross-border supply chain risk.

Commercial Impact

• Cost pressure: Tariffs on pharmaceutical inputs and bioprocessing equipment are raising production and logistics costs for vaccine developers and CDMOs operating across multiple regions
• Supply chain shifts: Companies are expanding local production capacity, qualifying alternative suppliers, and strengthening regional fill-finish operations to reduce tariff exposure and improve resilience
• Margin implications: Operational duplication and increased capital expenditure associated with supply chain regionalisation are placing pressure on programme economics, particularly for smaller developers
• Competitive positioning: Organisations with vertically integrated manufacturing and diversified supply networks are better positioned to manage cost volatility and maintain procurement competitiveness

Market Opportunities

Expanding mRNA Applications Across Oncology and Autoimmune Indications

The application scope of mRNA vaccines is expanding beyond infectious disease into oncology and immune-mediated conditions. Personalised cancer vaccine approaches have advanced into late-stage development, including mRNA-4157 (V940), which encodes up to 34 patient-specific neoantigens identified through tumour sequencing. In January 2026, Moderna and Merck announced five-year follow-up data showing that intismeran autogene in combination with pembrolizumab reduced the risk of recurrence or death by 49% in high-risk melanoma patients, reinforcing the long-term potential of mRNA-based oncology vaccines.

Beyond oncology, mRNA-based approaches are being explored in inflammatory bowel disease and other immune-mediated conditions, while advances in self-amplifying and circular RNA platforms alongside pulmonary delivery routes are extending application potential across multiple therapeutic areas.

Growth of Localised mRNA Manufacturing and Technology Transfer

The localisation of mRNA vaccine manufacturing is evolving from emergency response into structured ecosystem development underpinned by formal technology transfer frameworks. The modular architecture of mRNA production supports scalable hub-and-spoke models, with the WHO-Medicines Patent Pool mRNA Technology Transfer Programme enabling coordinated training and process transfer to regional manufacturers. In February 2026, Kenya joined the programme, enabling local scientists and manufacturers to receive technical training in mRNA process development, quality control, and regulatory standards.

National policy alignment is reinforcing this transition, with governments prioritising upstream competencies in mRNA synthesis and platform technologies beyond fill-finish roles, and aligning research funding and industrial collaboration to build domestically anchored vaccine ecosystems.

Competitive Landscape

The major players operating in the mRNA vaccines market include AIM Vaccine, Arcturus Therapeutics, BioNTech SE, DAIICHI SANKYO, etherna, Ethris, GSK plc, Moderna, Pfizer, Sanofi, and Strand Therapeutics.

These companies are strengthening their market positions through M&A, R&D investment, strategic collaborations, and regional manufacturing expansion, with increasing focus on personalised oncology programmes and next-generation platform development.

Recent Developments

• January 2026 – Merck and Moderna reported five-year data from the KEYNOTE-942 study showing intismeran autogene in combination with pembrolizumab reduced recurrence or death risk by 49% in high-risk melanoma patients, reinforcing the long-term potential of personalised mRNA cancer immunotherapy
• October 2025 – The European Investment Bank and European Commission partnered with BioNTech on a blended financing package of up to €95 million to expand BioNTech’s mRNA manufacturing facility in Kigali, Rwanda, supporting regional vaccine production and clinical capabilities across Africa
• September 2025 – The UK Government announced a £50 million life sciences fund alongside plans to expand vaccine manufacturing capacity in Oxfordshire, supporting domestic production of next-generation vaccines and strengthening pandemic preparedness capabilities
• May 2025 – BioNTech pledged up to £1 billion in UK R&D investment over ten years, supported by a government grant of up to £129 million, to establish AI-enabled research centres in Cambridge and London and strengthen the UK’s advanced medicines pipeline

Frequently Asked Questions

What is driving growth in the mRNA vaccines market?

Growth is driven by advances in lipid nanoparticle delivery systems, the clinical maturation of self-amplifying mRNA platforms, expanding application across oncology and autoimmune indications, and increasing government investment in domestic mRNA manufacturing infrastructure.

How are trade and supply chain dynamics affecting the market?

Tariffs on pharmaceutical inputs and bioprocessing equipment are increasing production costs for vaccine developers and CDMOs. This is accelerating supply chain regionalisation, with companies investing in local manufacturing capacity and diversified supplier networks to reduce cross-border dependencies.

Who are the leading companies in the market?

Key players include BioNTech SE, Moderna, Pfizer, GSK, Sanofi, Arcturus Therapeutics, and Strand Therapeutics.

Related Reports

Vaccine Contract Manufacturing Market Report 2026–2036

mRNA Cancer Vaccine Market Report 2026–2036

Download Sample Request

About Visiongain

Established in 1998, Visiongain is an independent publisher of analyst-led market intelligence, delivering data-driven research, forecasts, and strategic insight across global industries and emerging markets. Visiongain supports evidence-based decision-making for investment, procurement, and long-term strategic planning.

Media Contact

press@visiongain.com
+44 (0)20 7336 6100
www.visiongain.com